By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Dynamic Business Location.

Novartis invests EUR 100 million

Sandoz plant in Schaftenau © Novartis

The subsidiary will be expanded to include, amongst other things, an integrated cell culture production, creating 190 new jobs. There originator biologicals from Novartis and biosimilars from Sandoz will be produced for the global market.

“Originator biologicals and biosimilars are the future of modern medicine. Novartis is a global leader in production and development in this field. Thanks to this investment we are even more pleased with the fact that the future of medicine will take place in Austria”, says Ard van der Meij, Country President of Novartis Austria.

Austrian quality for the world market

The Schaftenau plant is of major importance for Novelis due to the production of originator biologicals and biosimilars. This includes a focus product from Novartis pharmaceuticals for the therapy of psoriasis, psoriasis arthritis and Bektherev’s disease and two cost efficient Sandoz biosimilars. One of them is for the treatment of certain forms of blood cancer and immunological diseases, the other for the treatment of rheumatoid arthritis and other rheumatic illnesses. In 2014 and 2015, a global microparticle technology center and a state-of-the-art biologicals production for ready-to-fill syringes were open, and the production facilities were continuously expanded.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Meet us @ BIO-Europe

    25.10.2021 - 28.10.2021/ 07.30am - 06.00pm, Virtual Event

Austria Map

Find the perfect location for your company

Reliability and expertise in the country and in the company are the convincing factors in selecting a business location. We can be justifiably proud but can still become even more attractive. This is something Austria should increasingly work on in the future!

Pfizer

Logo
More testimonials

news from the business location Austria

Austria stands out due to its tax incentives for research

You want to know why companies such as Infineon, Siemens and Bosch have been carrying out research in Austria for decades? Contact us.

Lynus – the software for the enegery-optimized building of the future.

The business location Austria offers innovative businesses such as Lynus the right platform, a modern environment, and highly skilled workforce in order to use complex IOT solutions with ease. Additionally the desire of a lot of Austrian companies to minimize their CO2 footprint in a sustainable way, appeals very much to our business model.

More news All blog posts